Fig. 1.

Targets of newly approved and potential future therapies for reducing TRL, LDL-C and lipoprotein (a) (Lp(a)) levels and increasing HDL-C levels. ApoC-III (blue) inhibits LPL and hepatic lipase (HL) and prevents the uptake of TRLs and their remnants by the liver. ANGPTL3 (green) may increase VLDL secretion, inhibits LPL and endothelial lipase (EL) and prevents the uptake of LDL in the liver. PCSK9 (orange) promotes LDL receptor degradation in lysosomes of hepatocytes. CETP (white) promotes the exchange of triglycerides and cholesteryl esters from HDL to apoB-containing lipoproteins. Newly approved and potential future therapies are shown in red. ANGPTL3, angiopoietin-like 3; Apo, apolipoprotein; CETP, cholesteryl ester transfer protein; LDLR, low-density lipoprotein receptor; LPL, lipoprotein lipase; PCSK9, proprotein convertase subtilisin/kexin 9. This figure is available as a downloadable slide